Results 101 to 110 of about 3,573 (200)

Real-world experience of galcanezumab in the prevention of migraine in Spain: a systematic literature review [PDF]

Targeting therapies; Migraine; Monoclonal antibodiesTeràpies dirigides; Migranya; Anticossos monoclonalsTerapias dirigidas; Migraña; Anticuerpos monoclonalesIntroduction: In the context of migraine preventive therapy, new therapeutic modalities such as ...
de Paz Fernández, Héctor David, Díaz-Cerezo, Silvia, Fernández-Montoya, Julia, Garcia Azorin, David, Núñez, Mercedes, Pozo-Rosich, Patricia   +5 more
core   +2 more sources

Monoclonal antibodies for migraine: an update [PDF]

, 2018
Castle, Daniel, Robertson, Neil P.
core   +2 more sources

Adverse and serious adverse events incidence of pharmacological interventions for managing chronic and episodic migraine in adults: a systematic review [PDF]

Background: Migraine is the second most common prevalent disorder worldwide and is a top cause of disability with a substantial economic burden. Many preventive migraine medications have notable side effects that affect different body organs.
Aksentyte, Aiva, Brown, Anna, Davies, Natasha, Duncan, Callum, Matharu, Manjit, Mistry, Hema, Naghdi, Seyran, Underwood, Martin   +7 more
core  

Comparison of Treatment Patterns in Patients with Migraine Initiating Calcitonin Gene-Related Peptide Monoclonal Antibodies: A Retrospective Real-World US Study

Patient Preference and Adherence
Oralee J Varnado,1 Brenna L Brady,2 Anthony J Zagar,1 Yvonne P Robles,2 Margaret Hoyt1 1Eli Lilly and Company, Indianapolis, IN, USA; 2Merative, Ann Arbor, MI, USACorrespondence: Oralee J VarnadoValue, Evidence, and Outcomes, Eli Lilly and Company, Lilly
Varnado OJ, Brady BL, Zagar AJ, Robles YP, Hoyt M   +4 more
doaj  

Efficacy and safety of erenumab for nonopioid medication overuse headache in chronic migraine a phase 4, randomized, placebo-controlled trial [PDF]

IMPORTANCE Patients with chronic migraine and medication overuse headaches (CM-MOH) represent a particularly burdened subpopulation. This trial provides first, to our knowledge, American Academy of Neurology class I evidence for a preventive therapy in ...
Chehrenama, Mahan, Chou, Denise E., Dodick, David W., Dolezil, David, Gil-Gouveia, Raquel, Lanteri-Minet, Michel, Lima, Gabriel Paiva da Silva, Lucas, Christian, Mikol, Daniel D., Piasecka-Stryczynska, Karolina, Szabo, Gyoengyi, Tepper, Stewart J., Yang, Yiping   +12 more
core   +1 more source

A case of erenumab, a new migraine medication, and delayed wound and bone healing after foot and ankle surgery

Foot & Ankle Surgery: Techniques, Reports & Cases
Patient selection and optimization are crucial components of successful surgery outcomes. Erenumab is a Calcitonin Gene-Related Peptide (CGRP) antagonist that was recently approved by the FDA for the treatment of migraines.
Timothy Cheung, DPM, PhD, CPT, Zachary Korwek, DPM, Arij Rashid, DPM, AACFAS, Rumzah Paracha, MD, Ashley Bruno, DPM, FACFAS   +4 more
doaj   +1 more source

Structural basis for adhesion G protein-coupled receptor Gpr126 function [PDF]

, 2020
Araç, Demet, Cunningham, Rebecca L., Feldman, Ezra, Leon, Katherine, Li, Jingxian, Monk, Kelly R., Riback, Joshua A., Sosnick, Tobin R., Zhao, Minglei   +8 more
core   +2 more sources

Calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab

Journal of Pain Research, 2017
Maria Adele Giamberardino,1,* Giannapia Affaitati,1,* Raffaele Costantini,2 Francesco Cipollone,3,* Paolo Martelletti4,* 1Department of Medicine and Science of Aging, Headache Center, Geriatrics Clinic and Ce.S.I.-Met, “G.
Giamberardino MA, Affaitati G, Costantini R, Cipollone F, Martelletti P   +4 more
doaj  

Erenumab in chronic migraine with medication overuse:Subgroup analysis of a randomized trial [PDF]

, 2019
Ashina, Messoud, Brandes, Jan Lewis, Cheng, Sunfa, Diener, Hans Christoph, Friedman, Deborah I., Lenz, Robert A., Leonardi, Dean K., Mikol, Daniel D., Nilsen, Jon, Reuter, Uwe, Tepper, Stewart J.   +10 more
core   +1 more source

Anti-CGRP receptor antibodies do not modulate trigeminal pain processing: indication for distinct mechanisms of CGRP pathway blockade. [PDF]

J Headache Pain
Peng KP, Basedau H, Messlinger K, May A.
europepmc   +1 more source